AUA: Positive Long-Term Survival Outcomes With Cyberknife Prostate SBRT for Intermediate Risk Prostate Cancer
Accuray announced outcome data from a prospective monotherapy study evaluating the Cyberknife Prostate SBRT (stereotactic body radiation therapy) in intermediate risk prostate cancer patients. Cyberknife Prostate SBRT, a 5-day non-invasive treatment, was administered to 81 intermediate-risk organ confined prostate cancer patients. Patients had a median follow-up of four years, including 24 patients with a minimum of 5 years follow up.
Relapse-free survival at four years was observed in 91% of patients. This rate was comparable to surgical and non-surgical treatments in this patient population, but Cyberknife Prostate SBRT was associated with similar to improved toxicity outcomes.For more information visit www.accuray.com.